Skip to content

iPS Cells of Patients for Models of Retinal Dystrophies

iPS Cells of Patients for Models of Retinal Dystrophies

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03853252
Acronym
RETIPS
Enrollment
150
Registered
2019-02-25
Start date
2014-11-03
Completion date
2023-10-30
Last updated
2025-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal Dystrophies

Brief summary

The investigators are focused on inherited retinal dystrophies with an aim to further understand disease pathophysiology and to elaborate novel treatments, as, to date, there is no effective treatment to prevent blindness. The main goal of this study is to generate human cellular models of healthy and disease retinas and perform studies to evaluate the efficiency of gene therapy approaches for different diseases. Skin biopsies of volunteers are cultured to isolate fibroblasts that are then reprogrammed into iPS cells. Healthy and disease-specific iPS cells are then differentiated into retinal models. This study should help to elucidate disease pathways and to provide proof-of-concept for various therapeutic approaches.

Interventions

OTHERSkin biopsy

Skin biopsy on a location preliminarily anesthetized Disinfection protocol Combined required blood tests (HIV, Hepatitis B)

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France
CollaboratorOTHER_GOV
University Hospital, Montpellier
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
5 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

: * Signed informed consent and * Choroideremia : * Males * CHM mutation * With multimodal Imaging anomalies in line with CHM * All other presumed inherited retinal dystrophies with bilateral and symmetrical involvement with identified mutations in one of the Retnet gene * All presumed inherited optic neuropathy with bilateral and symmetrical involvement with identified mutations * And in all cases or pattern * Age from 5 to 70 * with appropriate health insurance

Exclusion criteria

: * Patient under tutorship or curatorship

Design outcomes

Primary

MeasureTime frame
number of human cell models obtained10 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026